Arterial hypertension (AHT) is a major cardiovascular risk factor that leads to cardiovascular disease and target organ injury. Hypertension affects 1.4 billion adults worldwide. Around ~10% of hypertensive patients are classified as having secondary hypertension, but the etiology of AHT is unknown in 80-90% of cases, called essential hypertensives. Recent studies suggest that endocrine hypertension accounts for a significant proportion of patients with the latter form. Besides the obvious clinical phenotype with increased blood pressure, endocrine hypertensive patients have increased target organ injury due to fibrosis, inflammation, vascular remodeling, and dysfunction, oxidative stress, immune cell infiltration, and dysregulation. The search for novel or complementary biomarkers, including extracellular vesicles (EVs), is a highly active research field. Biomarkers, EVs and EV-cargos are suggested to be highly useful for patient’s stratification, diagnosis, and prognosis for endocrine hypertension, and are also lately studied as a novel therapeutic approach that could revolutionize the field.
The research topic expects to advance current knowledge for the discovery and potential use in diagnosis and therapeutics of novel biomarkers (e.g., proteins, RNA, miRNA, lipids, steroids) with a focus on including extracellular vesicles (EV) and EV-cargos.
Recent studies have reported a role for potential biomarkers, especially EVs and EV-cargos, in normal physiology and pathophysiological responses associated with hypertension. EVs have been highlighted for their potential as a form of liquid biopsy and contain a reservoir of multiple types of “cargo” including cell-specific miRNA and proteins. Hence EVs have enormous potential for biomarker discovery and further development of novel therapeutic strategies that target cell-to-cell communication.
We expect researchers to contribute to this special issue with original research papers or review articles regarding novel biomarker discovering studies.
These can include the extracellular vesicles to enlighten metabolic and pathophysiological aspects affecting cardiovascular health associated with endocrine systems and tissues such as, but not limited to, adrenal, renal, cardiac, liver, vascular, and fat.
Contributions can be reviews or original research articles relevant to biomarkers and extracellular vesicles in endocrine hypertension and related disorders.
Arterial hypertension (AHT) is a major cardiovascular risk factor that leads to cardiovascular disease and target organ injury. Hypertension affects 1.4 billion adults worldwide. Around ~10% of hypertensive patients are classified as having secondary hypertension, but the etiology of AHT is unknown in 80-90% of cases, called essential hypertensives. Recent studies suggest that endocrine hypertension accounts for a significant proportion of patients with the latter form. Besides the obvious clinical phenotype with increased blood pressure, endocrine hypertensive patients have increased target organ injury due to fibrosis, inflammation, vascular remodeling, and dysfunction, oxidative stress, immune cell infiltration, and dysregulation. The search for novel or complementary biomarkers, including extracellular vesicles (EVs), is a highly active research field. Biomarkers, EVs and EV-cargos are suggested to be highly useful for patient’s stratification, diagnosis, and prognosis for endocrine hypertension, and are also lately studied as a novel therapeutic approach that could revolutionize the field.
The research topic expects to advance current knowledge for the discovery and potential use in diagnosis and therapeutics of novel biomarkers (e.g., proteins, RNA, miRNA, lipids, steroids) with a focus on including extracellular vesicles (EV) and EV-cargos.
Recent studies have reported a role for potential biomarkers, especially EVs and EV-cargos, in normal physiology and pathophysiological responses associated with hypertension. EVs have been highlighted for their potential as a form of liquid biopsy and contain a reservoir of multiple types of “cargo” including cell-specific miRNA and proteins. Hence EVs have enormous potential for biomarker discovery and further development of novel therapeutic strategies that target cell-to-cell communication.
We expect researchers to contribute to this special issue with original research papers or review articles regarding novel biomarker discovering studies.
These can include the extracellular vesicles to enlighten metabolic and pathophysiological aspects affecting cardiovascular health associated with endocrine systems and tissues such as, but not limited to, adrenal, renal, cardiac, liver, vascular, and fat.
Contributions can be reviews or original research articles relevant to biomarkers and extracellular vesicles in endocrine hypertension and related disorders.
